WHO Approves First Diagnostic Test for Bundibugyo Virus

The World Health Organization has taken a significant step in combating the ongoing Bundibugyo virus outbreak by approving the first molecular diagnostic test through its Emergency Use Listing (EUL) procedure. This approval marks a crucial milestone in the global response to what has become the largest recorded outbreak of Ebola disease caused by BDBV, which continues to spread across the Democratic Republic of the Congo and into Uganda.

The timing couldn’t be more critical. As of the announcement, the DRC alone has reported 1,406 laboratory-confirmed cases and 438 deaths. With cases continuing to mount, rapid and reliable diagnosis has become essential to identifying infections early, guiding timely patient treatment, and ultimately controlling the outbreak’s expansion.

Expanding Testing Capacity Where It Matters Most

What makes this approval particularly significant is how it addresses a real bottleneck in outbreak response. Before WHO’s expanded support, testing capacity was severely limited, concentrated primarily at two facilities in Kinshasa and Goma with a combined daily capacity of just 200-400 tests. That simply wasn’t enough to handle an outbreak of this scale.

Working with the Africa Centres for Disease Control and Prevention, WHO has helped establish a broader network of 10 laboratories across affected provinces. Today, that network boasts a reported capacity exceeding 2,000 tests daily. The newly approved diagnostic test will help maximize this expanded infrastructure, ensuring that healthcare workers and public health officials can confirm cases rapidly and accurately when seconds count.

Dr Yukiko Nakatani, WHO’s Assistant Director-General for Health Systems, Access and Data, emphasized the stakes: “During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission.”

How the EUL Process Works

WHO’s Emergency Use Listing procedure evaluates products on rigorous criteria including quality, safety, and performance based on available evidence. The process ensures that products meet minimum international standards while specifically addressing the needs of low- and middle-income countries where outbreaks typically take the heaviest toll.

This mechanism serves dual purposes. It accelerates access to reliable diagnostic tools during health emergencies while also helping UN procurement agencies and governments make informed decisions about which products to deploy in outbreak settings. It’s a balance between speed and confidence, recognizing that in a crisis, you need both.

Bundibugyo Virus: The Overlooked Threat

Bundibugyo virus represents one of three Ebola virus species known to cause large outbreaks in humans, yet it remains less familiar than its cousins. The virus spreads from animals to humans initially, then travels person-to-person through contact with sick individuals, the deceased, or contaminated bodily fluids and surfaces. Understanding transmission is key to prevention.

The current outbreak was officially declared a public health emergency of international concern on May 17, 2026. Within two weeks, WHO issued a call for manufacturers to submit diagnostic test applications for emergency listing. That rapid response demonstrates how seriously the global health community treats this threat.

Building the Diagnostic Arsenal

This approval represents just the beginning. Additional applications for Bundibugyo virus diagnostic tests remain under review through the EUL procedure, suggesting more options will soon be available. Meanwhile, WHO and Africa CDC, collaborating with organizations like PATH, FIND, and CHAI with support from Unitaid, are establishing a joint validation platform.

This platform will evaluate various diagnostic approaches: laboratory-based molecular tests, near-point-of-care molecular tests, and antigen rapid diagnostic tests. Generating real-world clinical evidence about how these products perform in actual outbreak settings is critical for optimizing response strategies.

The approval of this first diagnostic test isn’t just bureaucratic paperwork. It represents a commitment to protecting health security in vulnerable regions and a demonstration that global disease surveillance systems can activate quickly when threats emerge. As outbreaks continue to remind us why preparedness matters, the question remains: are we moving fast enough to stay ahead of the next crisis?

Source: World Health Organization